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We investigated CD81 T cell frequencies of five different Epstein–Barr virus-specific cytotoxic T lymphocyte epitopes
located within proteins of the replicative cycle and the latent state in healthy long-term virus carriers with IFN-g enzyme-
linked immunospot assay. Frequencies of the HLA-A3-restricted epitope RVRAYTYSK (RVR) whose minimal length was
mapped in this study to amino acid position 148–156 of the immediate-early protein BRLF1 were compared with those of a
further known HLA-A3-restricted epitope within EBNA3A, RLRAEAQVK (RLR). Determination of frequencies of CD81 T
lymphocytes directed against lytic antigen epitope RVR revealed that only one of eight donors recognized this epitope.
Frequency was calculated to be 65 RVR-specific CD81 T lymphocytes per 106 PBMC. None of the HLA-A3-positive donors
exhibited IFN-g release after antigenic stimulation with the EBNA3A-specific peptide epitope RLR. Furthermore, we chose
three known HLA-B8-restricted epitopes, RAKFKQLL (RAK), FLRGRAYGL (FLR), and QAKWRLQTL (QAK), of the lytic protein
BZLF1 and the latent protein EBNA3A. Examination of eight HLA-B8-positive virus carriers revealed that the BZLF1-specific
epitope RAK was recognized by all donors with a median frequency of 233 RAK-specific CD81 T lymphocytes per 106 PBMC.
Only 50% of these donors reacted against EBNA3A-specific epitope FLR and a minority (25%) reacted against EBNA3A-
specific epitope QAK. © 1999 Academic Press
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oINTRODUCTION
Epstein–Barr virus (EBV) is a ubiquitous human gam-
aherpesvirus with a wide dissemination in all human
opulations, with prevalences of more than 90% (Ma-
ucci and Ernberg, 1994). Like all other herpesviruses,
BV can establish both nonproductive (latent) and pro-
uctive (lytic) infections within the cells of its host. The
irus is the causative agent of infectious mononucleosis,
ut has also been implicated in the etiology of an in-
reasing number of human malignancies, including Bur-
itt’s lymphoma, undifferentiated nasopharyngeal carci-
oma, and B cell lymphomas in immunocompromised
ndividuals, and more recent evidence suggests an as-
ociation with Hodgkin’s lymphoma (Rickinson and
oss, 1997). In the immunocompetent host, however, the
utgrowth of EBV-infected cells and uncontrolled produc-
ion of virions are efficiently prevented by immune mech-
nisms such as natural killer cells, antibody-dependent
ellular cytotoxicity (Jilg et al., 1994), neutralizing antibod-
es (reviewed by Khanna et al., 1995), and above all
pecific cytotoxic T lymphocytes (CTL). These HLA-class
-restricted CD81 CTL are directed against proteins of
1 To whom correspondence and reprint requests should be ad-
ressed at Institut fu¨r Medizinische Mikrobiologie und Hygiene, Uni-
ersita¨t Regensburg, Franz-Josef-Strauss-Allee 11, D-93053 Regens-
urg, Germany. Fax: 149-941-9446402. E-mail: wolfgang.jilg@klinik.eni-regensburg.de.
289atency (Kienzle et al., 1998; summarized by Rickinson
nd Moss, 1997) and the replicative cycle (Bogedain et
l., 1995; Pepperl et al., 1998; Redchenko and Rickinson,
999; Steven et al., 1997; White et al., 1996). During
ersistence the virus is harbored by a small number of B
ells in which the expression of most if not all viral latent
roteins is downregulated (Thorley-Lawson et al., 1996).
s EBV can switch directly from the latent state into the
ytic cycle without any expression of further latent pro-
eins (Rowe et al., 1992), CTL directed against these
roteins might not be able to prevent the ongoing viral
eplication.
Therefore increasing interest concentrated on the con-
rol of the lytic cycle of EBV infection since immune
ontrol mechanisms directed against immediate-early
roteins would efficiently suppress production and re-
ease of progeny virions. Recent work from our group
emonstrated that immediate-early proteins BZLF1 and
RLF1 are targets of CD81 T lymphocytes (Bogedain et
l., 1995; Pepperl et al., 1998). Hierarchies of antigen-
pecific CTL responses have been observed following
nfection of mice and humans with many different patho-
enic organisms (reviewed by Gallimore et al., 1998).
etermination of the hierarchy of EBV immunodominant
TL epitopes is an important aim of EBV research since
pecific CTL can be used for prophylaxis and treatment
f EBV-associated diseases (Haque et al., 1998; Heslop
t al., 1996; Heslop and Rooney, 1997; Kuzushima et al.,
0042-6822/99 $30.00
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290 BENNINGER-DO¨RING ET AL.996; Rooney et al., 1998a,b; Roskrow et al., 1998;
uhrbier, 1997). Indeed, there is accumulating evidence
or a hierarchy among the immunogenic CTL epitopes
ithin proteins of latency (Khanna et al., 1997; Levitsky et
l., 1998) and the replicative cycle (Tan et al., 1999). The
mportance of EBV-specific CTL epitopes of latent and
ytic cycle proteins can be evaluated by determination of
requencies of CD81 T lymphocytes. In the past such
requencies have been detected using limiting dilution
nalysis; this method, however, requires a great deal of
ork and is time-consuming, as in most cases several
ounds of stimulation of effector cells are necessary
Taswell, 1981). One alternative method for the analysis
f frequencies of specifically reacting T cells is the en-
TABLE 1
Fine-Mapping of the CTL Epitope between Amino Acid Positions
145 and 159 of Rta Recognized in the Context of HLA-A3
Peptide
Amino acid
sequence
% Specific
lysisa
SFC/2 3 105
PBMCb
ta145–159 KHSRVRAYTYSKVLG 36 6 5 5 6 2
ta148–159 RVRAYTYSKVLG 40 6 10 5 6 2
ta149–159 VRAYTYSKVLG 34 6 7 7 6 2
ta150–159 RAYTYSKVLG 5 6 3 1 6 1
ta145–157 KHSRVRAYTYSKV 23 6 12 7 6 5
ta145–156 KHSRVRAYTYSK 28 6 10 12 6 4
ta145–155 KHSRVRAYTYS 3 6 3 0 6 1
ta145–154 KHSRVRAYTY 2 6 2 0 6 0
ta148–156 RVRAYTYSK 53 6 7 11 6 2
ta149–156 VRAYTYSK 2 6 0 1 6 1
a Specific lysis was obtained by subtracting the lysis of target cells
ulsed with the control peptide HIV-Env from the lysis of target cells
ulsed with nine shortened versions of peptide Rta145–159. The E:T ratio
as 20:1. The results are given as means 6 standard errors of the
eans. Data for three independent experiments are shown.
b The numbers of cells secreting IFN-g in response to peptides
erived from EBV lytic antigen BRLF1145–159 are shown. Nonspecific
FN-g secretion obtained by stimulation with control peptide HIV-Env
as subtracted. PBMC were seeded at a concentration of 2 3 105
BMC and cultured for at least 24 h in the presence of a 2.5 3 1026 M
oncentration of the truncated peptide version. Results of four indepe-
ent experiments with five replicates are given as means 6 standard
rrors of the means.
T
MHC Class I-Restricted CTL Epito
EBV protein Epitope sequence Epitop
Lytic cycle antigens
BZLF1 RAKFKQLL 19
BRLF1 RVRAYTYSK 1
Latent antigens
EBNA3A FLRGRAYGL 3
EBNA3A QAKWRLQTL 1
EBNA3A RLRAEAQVK 6
HIV-Env RIGPGRAFVTIGyme-linked immunospot (ELISPOT) assay, which de-
ects single IFN-g-secreting T cells. This test, rendered
pecific for CD81 T cells by using peptides of optimized
ength for stimulation, seems suitable for rapidly screen-
ng individuals for their level of specific T cell reactivity.
LISPOT assays with the sensitivity to detect and quan-
itate peptide-specific T cells among PBMC without the
eed for in vitro restimulations have been described for
ifferent viral, bacterial, and tumoral systems (Herr et al.,
997, 1998; Lalvani et al., 1997; Lalvani and Hill, 1998;
ohr et al., 1998; Rowland-Jones et al., 1998; Scheiben-
ogen et al., 1997a,b; Schmittel et al., 1997).
In the present study we used this technique to analyze
he frequency of CD81 T cells specific for two lytic cycle
eptides derived from EBV proteins BZLF1 and BRLF1
nd three from the latent protein EBNA3A. All epitopes
ere restricted to either HLA-A3 or HLA-B8. The HLA-
3-restricted BRLF1 epitope was first described recently
y our group (Pepperl et al., 1998); for this work we
apped its minimal amino acid sequence by IFN-g
LISPOT and standard chromium release assays. Here
e present the data on the frequencies of CD81 T cells
ith specificities for these epitopes obtained in a study
roup consisting of 12 healthy individuals with long-
asting persistent EBV infection, 8 individuals positive for
LA-A3, and 8 individuals positive for HLA-B8.
RESULTS
etermination of the minimal length of CTL epitope
ta145–159 of BRLF1
The peptide Rta145–159 derived from the immediate-early
rotein BRLF1 was shown to be an effective target for
BV-specific CTL restricted by HLA-A3 (Pepperl et al.,
998). For the studies described here we determined the
inimal length of the recognized epitope with shortened
ersions of immunogenic peptide Rta145–159 using cells of
onor 7. We identified the nonameric sequence RVRAY-
YSK (RVR), corresponding to amino acids 148–156 of
he BRLF1 protein, as an optimally reacting structure
data are summarized in Table 1).
m EBV Lytic and Latent Proteins
tion HLA restriction Reference
B8 Bogedain et al. (1995)
A3 This study
B8 Burrows et al. (1994)
B8 Khanna et al. (1995)
A3 Hill et al. (1995)
Takahashi et al. (1990)ABLE 2
pes fro
e loca
0–197
48–156
25–333
58–166
03–611
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291FREQUENCY OF EBV-SPECIFIC CD81 T LYMPHOCYTESrequency of T cells recognizing immediate-early and
atent proteins of EBV
Twelve EBV-positive donors expressing HLA-A3
nd/or B8 were tested for T cells reacting with peptides
erived from the immediate-early EBV proteins BZLF1
nd BRLF1 and the latent protein EBNA3A (summarized
n Table 2), by determination of IFN-g-secreting cells
sing an ELISPOT assay. One EBV-negative donor who
as HLA-A3- and B8-positive served as control (donor
3).
All eight HLA-B8-positive individuals showed a signif-
cant response to the B8-restricted BZLF1-derived pep-
ide RAK. Five of these donors responded to the also
8-restricted EBNA3A epitopes: three to FLR, one to
AK, and one to both FLR and QAK. On the other hand,
nly one of the eight HLA-A3-positive donors reacted to
ne of the A3-restricted peptides, donor 7, who showed
moderate reaction to the immediate-early protein
RLF1. None of the HLA-A3-expressing donors recog-
ized EBNA3A peptide RLR (Table 3).
The frequency of IFN-g-secreting cells in association
ith BZLF1-specific peptide RAK was calculated to be
etween 35 and 990 cells/106 PBMC, that for EBNA3A-
pecific peptide FLR was between 60 and 180 cells/106
BMC, and that for EBNA3A-specific peptide QAK was
0 cells/106 PBMC. In the one individual who showed a
esponse to BRLF1-derived RVR, the frequency was cal-
ulated to be 65 cells/106 PBMC.
These results were obtained by a standard ELISPOT
ssay using 2 3 105 PBMC per well. The use of larger
umbers of PBMC (5 3 105 and 106 cells per well) in
ertain cases (donors 1, 5, 8, and 9) did not change these
requencies significantly nor did it reveal any additional
ositive result (Table 4). Thus it can be supposed that the
umber of IFN-g-secreting cells was not underestimated
y possibly insufficient cell–cell contact using PBMC
oncentrations as low as 2 3 105 cells per well.
Removal of CD81 cells from PBMC abrogated IFN-g-
ecreting activity completely, whereas reconstitution
ith the CD81 fraction brought back the activity again,
onfirming that the IFN-g-secreting cells were indeed
D81 lymphocytes (Fig. 1).
recursor frequencies of antigen-specific CTL as
etected by limiting dilution analysis
Donors 5 and 7 were also evaluated for precursor
requencies of CTL directed against B8-restricted pep-
ides RAK, FLR, and QAK using limiting dilution analysis.
e found numbers of RAK-specific precursor CTL of 108
nd 1782 per 106 PBMC, respectively, for these two
onors (Fig. 2). Nine precursor CTL/106 PBMC against
he EBNA3A-specific peptide QAK were detected in the
lood of donor 7 (Fig. 2). The corresponding numbers ofFN-g-secreting cells directed against the same peptidesn donors 5 and 7 were 35,990 and 30 per 106 PBMC as
hown in Table 3.
DISCUSSION
All of the eight HLA-B8-positive, healthy long-term car-
iers of EBV showed high T cell reactivity against the
eptide RAKFKQLL derived from the EBV immediate-
arly protein BZLF1, with a median value of 233 CD81 T
ells per 106 PBMC specific for this epitope. On the other
and, CD81 T cells recognizing the HLA-B8-restricted
eptides FLR and QAK of the latent antigen EBNA3A
ere present to a significantly lesser degree as only four
nd two of the eight donors were able to react with FLR
nd QAK, respectively. Thus the RAK epitope turned out
o be a very important and possibly the dominant target
or specific cytotoxic T cells in HLA-B8-positive individ-
als with long-lasting persistent infection (in fact it was
he best recognized epitope in our experiments).
The immediate-early protein BZLF1 from which RAK is
erived plays a key role in the activation of EBV replica-
ion; it was described as the first immediate-early protein
o be expressed during the lytic cycle (Biggin et al., 1987)
nd initiates the expression of early genes (Rickinson
nd Moss, 1997). CTL directed against this protein
hould be able to eliminate virus producing cells at an
arly state, thus preventing release of infectious virions.
uch CTL therefore could control foci of virus replication
n the oropharynx as well as EBV-infected B cells switch-
ng spontaneously from latency to the lytic cycle without
rior expression of other latent proteins (Rowe et al.,
992).
BRLF1, another immediate-early protein of EBV, like
ZLF1, plays an important role during the switch from
atency to the lytic cycle in EBV-infected cells, as it is able
o disrupt latency in a cell-specific manner (Bogedain et
l., 1994; Ragoczy et al., 1998; Zalani et al., 1996). Steven
t al. (1997) were the first to show that this protein also
an act as a target for CTL; in an effort to analyze its
otential role for CTL control of EBV in more detail we
ere able to identify nine different CTL epitopes distrib-
ted over the entire protein sequence (Pepperl et al.,
998). For the present study we characterized the mini-
al epitope of one of these peptides restricted by HLA-
3. We found that the sequence RVRAYTYSK fits well the
escribed HLA-A3 motif—which predicts the nonpolar
mino acids L, V, or M at anchor position 2 and a
ydrophobic or basic residue at the C-terminus (Ram-
ensee et al., 1995)—as both these requirements are
ulfilled.
The analysis of CD81 T cells of our eight HLA-A3-
ositive donors, however, revealed only one of them
eacting to this epitope. None of these individuals
howed any response to the also HLA-A3-restricted
BNA3A epitope RLRAEAQVK.The results of our study confirm and extend the find-
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292 BENNINGER-DO¨RING ET AL.ngs of the very recent work of Tan et al. (1999). These
uthors similarly found that all of their seven HLA-B8-
ositive donors showed strong reactivity of CD81 cells
gainst RAK, whereas their responses against the
BNA3A peptide FLR were only moderate: three individ-
als showed a significantly lower response against the
BNA3A epitope than against the BZLF1 peptide and
ne donor showed no reaction at all in IFN-g ELISPOT.
These findings as well as our results extend earlier
indings that showed immunodominance of the RAK-
pecific CTL in healthy virus carriers and during acute
nfectious mononucleosis by limiting dilution analysis
Elliott et al., 1997; Steven et al., 1996), T cell receptor
nalysis (Silins et al., 1997), and the identification of
ntigen-specific CD81 T cells using fluorogenic HLA-B8
etramers (Callan et al., 1998). Thus there is now good
vidence that this epitope plays a significant role as a
arget for EBV-specific CD81 T cells in acute and latent
BV infection, at least in the hierarchy of the HLA-B8-
estricted epitopes known so far. Furthermore our finding
hat in the group of HLA-A3-positive individuals only the
pitope of the lytic protein BRLF1 is recognized fits the
bservation in the work of Tan et al. (1999) that T cells
pecific for EBV lytic proteins were usually more abun-
ant than those specific for latent epitopes.
The work presented here also demonstrates the use-
ulness of the ELISPOT assay for the analysis of frequen-
ies of CD8-positive T cells recognizing different pep-
ides. Certain requirements, however, are necessary to
uarantee the specificity of the test for CD81 T cells; thus
e used only the appropriate HLA-class I binding pep-
ides of optimized length for determination of CD81 T cell
requencies. A control experiment with cells of two do-
ors showed the abrogation of any specific activity after
BMC were depleted of CD81 T cells, whereas the
ctivity could be restored when CD81 cells were added
gain. A comparison of the precursor frequency of three
pecific CTL determined by LDA in two donors with the
alues of the ELISPOT test showed results on the same
rder of magnitude (two values were two and three times
igher in LDA, and one value was three times higher in
he ELISPOT assay).
The ELISPOT test and limiting dilution analysis using
hromium release assays may underestimate the fre-
uencies of total peptide-specific T cells. This could
ither be due to the presence of specific T cells that
anifest effector functions other than IFN secretion or
ytotoxity or be due to the presence of nonresponsive
eptide-specific cells. The frequency and significance of
uch cells, however, are difficult to estimate, as conflict-
ng data have been published thus far regarding the
ensitivity of different assays used for measuring human
lymphocyte functions: Tan et al. (1999), using the tet-
amer technology (which should be able to detect all
eptide-specific T cells irrespective of their function),described higher values of specific T cells, whereasA BZ BR EB EB EB H W EB 10 of
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293FREQUENCY OF EBV-SPECIFIC CD81 T LYMPHOCYTESther groups could not find significant differences be-
ween T cell frequencies detected by either tetramers or
LISPOT assays (Hickling, 1998).
One important conclusion from our work is that the
ood recognition of immediate-early proteins like BZLF1
annot be generalized. Only one of eight HLA-A3-posi-
ive individuals showed a response to the HLA-A3-re-
T
Serial Dilution of the Input Number of PB
Antigen
Antigenic
peptide
Restricting
MHC class I
molecule
Donor 1
106
PBMC
5 3
105
PBMC
2.5 3
105
PBMC
10
PBM
ZLF1 RAK B8 36
RLF1 RVR A3 1 0 1 1
BNA3A FLR B8 1
BNA3A QAK B8 0
BNA3A RLR A3 2 1 1 0
IV-Env 0 0 0 0
ithout
antigen 0 0 0 0
Note. The numbers of cells secreting IFN-g in response to peptides
ntigen EBNA3A325–333, EBNA3A158–166, and EBNA3A603–611 in PBMC of four
n serial dilutions at concentrations of 1 3 106, 5 3 105, and 2.5 3 105 P
ositive results are shown in boldface type and underlined.
FIG. 1. The number of cells secreting IFN-g in response to HLA-B8-r
ells (donor 6 (E) and donor 7 (F)). Constant numbers of CD8-depleted
5,000 CD81 cells. In both donors, who are HLA-B8 positive, the mean
xperiments is shown. The number of nonspecific spots in the presence of Htricted epitope RVR of BRLF1, although the biological
mportance of this protein is probably similar to the
mportance of the BZLF1. As there is no HLA-A3 epitope
n BZLF1 (Bogedain et al., 1995) and as none of the eight
onors responded to the latent peptide RLR, which is the
nly HLA-A3 restricted among the 46 epitopes derived
rom latent proteins known so far (Rickinson and Moss,
Donor 1, Donor 5, Donor 8, and Donor 9
nor 5 Donor 8 Donor 9
5 3
105
BMC
2.5 3
105
PBMC
106
PBMC
5 3
105
PBMC
2.5 3
105
PBMC
106
PBMC
5 3
105
PBMC
2.5 3
105
PBMC
14 5 48 32 17 48 42 26
3 0 1 0 0
3 0 76 55 28 47 34 26
0 0 0 6 3 26 11 3
3 0 1 0 0
0 0 1 0 0 0 0 0
0 1 0 0 0 4 3 1
d from EBV lytic antigen BZLF1190–197, lytic antigen BRLF1148–156, latent
nt HLA-A3- and/or -B8-positive donors are shown. PBMC were seeded
nd cultured for at least 24 h in the presence of 2.5 3 1026 M peptide.
d BZLF1-specific peptide RAK, dependent on the presence of CD81 T
50,000 cells) were tested without and after readdition of 0, 10,000, and
r of RAK-specific spots 6 SEM (of five replicates) in two independentABLE 4
MC of
Do
6
C P
derive
differe
BMC aestricte
cells (1
numbeIV-Env peptide was subtracted.
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294 BENNINGER-DO¨RING ET AL.997), one could argue that HLA-A3-positive individuals
re disadvantaged with regard to their CTL response
gainst EBV. However, nothing suggests less efficient
ontrol of EBV-infected cells and viral replication in these
ndividuals. They possess two to five additional MHC
lass I antigens of different types, which could be restric-
ion elements for other epitopes (thus, four of our donors
ere HLA-B8-positive, showing a good response to
ZLF1, and two of them also responded to EBNA3A).
urthermore, it must be stressed that at present in con-
rast to latent proteins only a small minority of the prob-
bly more than 70 proteins expressed during the lytic
ycle of EBV have been analyzed for their possible role
s targets for cellular immune reactions; it may well be
hat in the future we will detect even more powerful CTL
pitopes among lytic antigens than we have identified so
ar.
Thus we still are far away from a complete under-
tanding of the control of EBV-infected cells by cellular
mmune mechanisms. As defects in these mechanisms
ould be the key to the pathogenesis of EBV-related
iseases associated with active viral replication, e.g.,
hronic active EBV infection (Khanna et al., 1995), further
tudies identifying new target peptides for CTL as well
s frequencies of CTL reacting with these peptides seem
o be of particular importance.
MATERIALS AND METHODS
tudy population
Thirteen normal healthy individuals were tested by
LISA for anti-EBV antibodies against EBNA1 and EBV
FIG. 2. Determination of precursor frequencies of HLA-B8-restricted
A) and donor 7 (B). Sets of replicate cultures (n 5 24), derived from we
eptide-coated PHA blast targets. At each cell input number, results
pitope-specific CTL frequency was then calculated by the method of m
egative (95% confidence limit). HLA-B8-restricted BZLF1-specific CTL e
pitope QAK (E).arly antigen (Biotest, Dreieich, Germany). All of them Tere EBV-seropositive for at least 5 years, except donor
3, who was EBV-seronegative. HLA types from these
onors were determined by standard serological tech-
iques. HLA-A and -B types were as follows: Donor 1, A2,
3, B18, B62; donor 2, A2, A3, B57, B60; donor 3, A3, A10,
7, B44; donor 4, A3, A26, B38, B51; donor 5, A3, A24, B8,
61; donor 6, A1, A3, B8, B51; donor 7, A1, A3, B7, B8;
onor 8, A1, A3, B7, B8; donor 9, A1, A2, B8, B62; donor 10,
1, B8, B37; donor 11, A1, A2, B8, B56; donor 12, A1, A9,
8, B27; and donor 13, A1, A3, B7, B8.
LISPOT assay for single-cell IFN-g release:
etection of antigen-specific effectors
rom freshly isolated PBMS
Ninety-six-well nitrocellulose plates (MAHA S45, Mil-
ipore, Eschborn, Germany) were coated with monoclo-
al antibody anti-IFN-g Mab 1-D1K (10 mg/ml) (Ho¨lzel,
ologne, Germany) overnight at 4°C. Plates were then
ashed five times with phosphate-buffered saline and
locked with RPMI 1640 supplemented with L-glutamine,
anamycin, and 10% heat-inactivated pooled human AB
erum (R10) (all from PanSystems, Aidenbach, Germany)
or 1 h. PBMC were separated from heparinized blood
sing Ficoll-Histopaque density gradient centrifugation,
ashed three times, and resuspended in R10. A total of
3 105–106 PBMC were added in 100 ml R10/well to the
recoated plates in five replicate wells. Peptides were
dded at a concentration of 2.5 3 1026 M. Assays were
ncubated for 20–40 h at 37°C, 5% CO2 and the reaction
as stopped by washing the plates eight times with
ash solution (phosphate-buffered saline 1 0.05%
itopes of BZLF1 and EBNA3A by limiting dilution analysis of donor 5
ded with increasing cell numbers, were screened against autologous,
ch epitope are expressed as the percentage of negative wells. The
m likelihood and is determined as the point at which 37% of wells are
RAK (F), EBNA3A-specific CTL epitope FLR (), EBNA3A-specific CTLCTL ep
lls see
for ea
aximu
pitopeween 20 (Sigma, Deisenhofen, Germany). Next 100 ml of
t
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295FREQUENCY OF EBV-SPECIFIC CD81 T LYMPHOCYTEShe biotinylated antibody anti-IFN-g Mab 7-B6-1-biotin (1
g/ml) (Ho¨lzel) was added. After 3 h of incubation at
oom temperature, plates were washed six times with
ash solution. One hundred microliters of streptavidin
lkaline phosphatase conjugate (1 mg/ml) (Ho¨lzel) was
dded to each well and plates were incubated for a
urther 2 h at room temperature. Wells were again
ashed six times and 100 ml of chromogenic alkaline
hosphatase substrate (Boehringer, Germany) dissolved
n deionized water was added. After 5–15 min, the col-
rimetric reaction was terminated by washing with
eionized water and plates were air-dried. Colored spots
ere counted using a stereomicroscope. Responses
ere considered significant if a minimum of five IFN-g
pot-forming cells were present per well, and addition-
lly this number was at least twice as high as in negative
ontrol wells.
eparation of CD81 cells from freshly isolated PBMC
CD81 cells were removed from PBMC of donors 6 and
using MACS magnetic cell separation system CD8
icroBeads (Miltenyi Biotec, Bergisch Gladbach, Ger-
any) as described in the manufacturer’s protocol.
ynthetic peptides
All peptides were synthesized on a Model 9050 syn-
hesizer (Milligen, Eschborn, Germany) by using fluo-
enylmethyloxycarbonyl chemistry as described else-
here (Modrow et al., 1989) and purified by HPLC (Phar-
acia, Uppsala, Sweden).
TL lines
EBV-specific CTL lines were established as described
reviously (Bogedain et al., 1995). In brief, PBL were
urified by density gradient centrifugation using Ficoll-
istopaque (Sigma) and cultivated for 4–7 days in T cell
edium (RPMI 1640 medium with 10% heat-inactivated
uman serum, 2 mM glutamine, 1% nonessential amino
cids, 2 mM sodium pyruvate, and 10 mg/ml gentamycin
r kanamycin (all from PanSystems). T cells were stim-
lated weekly with peptide-pulsed, irradiated PHA blasts
t a stimulator:responder ratio of 10:1 in the presence of
0 U/ml recombinant human IL-2 (PanSystems). For puls-
ng stimulator cells peptides were used at concentra-
ions of 1026 M. After 2 to 3 weeks of stimulation CTL
ines were tested for cytotoxicity.
ytotoxicity assays
Cytotoxicity assays were performed as described pre-
iously (Bogedain et al., 1995). Briefly, 106 autologous or
llogenic target cells were labeled for 1–2 h with 0.15
Ci of Na51 CrO4 (DuPont, Bad Homburg, Germany) and
oaded with synthetic peptide for 1 h at a concentration
f 4 3 1027 M in a final volume of 25 ml. Then target cellsere coincubated with different numbers of effector cells
uspended in 100 ml for 4 h in V-bottom 96-well plates.
lates were then centrifuged and the supernatant was
arvested for determination of released chromium.
imiting dilution analysis
Precursor frequencies of EBV epitope-specific CTL
ere estimated from limiting dilutions of freshly isolated
BMC after in vitro stimulation with autologous irradiated
HA blasts pulsed with peptides. PBMC were cultured at
25 to 32,000 lymphocytes per well in 24 replicate wells
f 96-well microtiter plates. Stimulator cells were pre-
ared by incubating autologous PHA blasts with 1 mg/ml
f each peptide for 1 h, followed by irradiation with 50 Gy.
o each well of the precursor assay plate 5 3 104
-irradiated, peptide-coated stimulator cells were added.
ultures were fed with peptide-coated, autologous stim-
lator cells on days 4 and 7 with medium supplemented
ith 10% heat-inactivated AB serum and 20 U/ml IL-2
PanSystems). After 10–14 days, cells were split and
ssayed for cytotoxicity on 51Cr-labeled autologous PHA
lasts incubated for 1 h with the relevant peptides, PHA
lasts without peptide, or PHA blasts with control pep-
ide HIV-Env. Wells were scored negative if 51Cr release
id not exceed the mean plus 3 SD of the average
pontaneous release of the 24 control wells.
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